Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Infection of a human hepatoma cell line by hepatitis B virus
- P. Gripon, S. Rumin, +7 authors C. Guguen-Guillouzo
- Biology, Medicine
- Proceedings of the National Academy of Sciences…
- 13 November 2002
A cell line, called HepaRG, is described, which exhibits hepatocyte-like morphology, expresses specific hepatocyte functions, and supports HBV infection as well as primary cultures of normal human hepatocytes, suitable for many applications including drug metabolism studies. Expand
Statements from the Taormina expert meeting on occult hepatitis B virus infection.
Giovanni Raimondo*, Jean-Pierre Allain, Maurizia R. Brunetto, Marie-Annick Buendia, Ding-Shinn Chen, Massimo Colombo, Antonio Craxi, Francesco Donato, Carlo Ferrari, Giovanni B. Gaeta, Wolfram H.… Expand
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
- G. Davis, R. Esteban-Mur, +8 authors J. Albrecht
- The New England journal of medicine
- 19 November 1998
In patients with chronic hepatitis C who relapse after treatment withinterferon, therapy with interferon and oral ribavirin results in higher rates of sustained virologic, biochemical, and histologic response than treatment withInterferon alone. Expand
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus.…
AnInterferon alpha2b plus ribavirin combination is more effective than 48 weeks of interferonalpha2b monotherapy and has an acceptable safety profile. Expand
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.
cccDNA persists throughout the natural history of chronic hepatitis B, even in patients with serologic evidence of viral clearance, and long-term ADV therapy significantly decreased cccDNA levels by a primarily noncytolytic mechanism. Expand
Serological pattern “anti‐HBc alone”: Report on a workshop
Recommendations are given in relation to both the diagnostic and therapeutic procedures in the individuals with “anti‐HBc alone” and in the blood banking and transplantation services. Expand
Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure.
The observations suggest that a single amino acid change at position rt181 may induce cross-resistance to lamivudine and adefovir, and emphasize the clinical relevance of genotypic and phenotypic analysis in the management of antiviral drug resistance. Expand
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.
HCV-1-infected patients who can be maintained on >80% of their interferon or peginterferon alpha-2b and ribavirin dosage for the duration of treatment in the setting of a clinical trial exhibit enhanced sustained response rates. Expand
Impact of patatin‐like phospholipase‐3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C
The PNPLA3 (rs738409 C>G) polymorphism may represent a valuable genetic predictor and a potential therapeutic target inCHC liver damage and response to antiviral therapy in CHC. Expand
Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.
PEG-interferon and ribavirin combination significantly reduces the rate of fibrosis progression in patients with hepatitis C. Expand